Mycoplasma pneumoniae infections – Related resources
08.02.2012 • Sonuncu dəyişiklik 02.10.2007
This article is created and updated by the EBMG Editorial Team
Cochrane reviews
- There is insufficient evidence from trials about the benefits of antibiotic treatment for lower respiratory tract infections in children secondary to Mycoplasma pneumoniae .
Literature
- Ragnar Norrby S. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother 1997 Apr;39(4):499-508. J Antimicr Chemother 1997;39:499–508
Foy HM, Kenny GE, McMahan R, Mansy AM, Grayston JT. Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance. JAMA 1970 Nov 30;214(9):1666-72.
- Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology 2004 Mar;9(1):109-14.
- Gavranich JB, Chang AB. Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2005 Jul 20;(3):CD004875.
- Lode HM. Managing community-acquired pneumonia: a European perspective. Respir Med 2007 Sep;101(9):1864-73.
- Bartlett JG. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis 2008 Dec 1;47 Suppl 3():S232-6.